Linaclotide - Ironwood Pharmaceuticals

Drug Profile

Linaclotide - Ironwood Pharmaceuticals

Alternative Names: ASP-0456; ASP-456; Constella; Linaclotide acetate; Linzess; MD-1100; MM-416775

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Microbia
  • Developer Allergan; Astellas Pharma; AstraZeneca; Ironwood Pharmaceuticals
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Oligopeptides
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Constipation; Irritable bowel syndrome

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome
  • Preclinical Visceral pain

Most Recent Events

  • 26 Mar 2018 NCT03471728: Observational study, hence not added
  • 16 Jan 2018 Ironwood Pharmaceuticals and Allergan reach a settlement agreement with Sun Pharma to resolve linaclotide patent litigation
  • 10 Nov 2017 Astellas Pharma completes a phase III trial in Constipation in Japan (PO) (NCT02809105)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top